ZASOCITINIB, Matching Placebo for TAK-279
TAK-279-HS-2001
Phase 2 small_molecule active
Quick answer
ZASOCITINIB, Matching Placebo for TAK-279 for Hidradenitis Suppurativa is a Phase 2 program (small_molecule) at Takeda with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Takeda
- Indication
- Hidradenitis Suppurativa
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active